Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules.
J Immunol
; 176(3): 1525-33, 2006 Feb 01.
Article
en En
| MEDLINE
| ID: mdl-16424181
In both collagen-induced arthritis (CIA) and rheumatoid arthritis, T cells recognize a galactosylated peptide from type II collagen (CII). In this study, we demonstrate that the CII259-273 peptide, galactosylated at lysine 264, in complex with Aq molecules prevented development of CIA in mice and ameliorated chronic relapsing disease. In contrast, nonglycosylated CII259-273/Aq complexes had no such effect. CIA dependent on other MHC class II molecules (Ar/Er) was also down-regulated, indicating a bystander vaccination effect. T cells could transfer the amelioration of CIA, showing that the protection is an active process. Thus, a complex between MHC class II molecules and a posttranslationally modified peptide offers a new possibility for treatment of chronically active autoimmune inflammation such as rheumatoid arthritis.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Péptidos
/
Artritis Experimental
/
Vacunas
/
Antígenos de Histocompatibilidad Clase II
/
Inmunoterapia Activa
/
Colágeno Tipo II
/
Complejos Multiproteicos
Idioma:
En
Revista:
J Immunol
Año:
2006
Tipo del documento:
Article
País de afiliación:
Suecia